MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
32.62
+1.24
+3.95%
After Hours: 31.97 -0.65 -1.99% 19:30 06/11 EDT
OPEN
31.43
PREV CLOSE
31.38
HIGH
32.72
LOW
31.09
VOLUME
1.82M
TURNOVER
--
52 WEEK HIGH
43.73
52 WEEK LOW
6.59
MARKET CAP
5.57B
P/E (TTM)
-15.1488
1D
5D
1M
3M
1Y
5Y
1D
Cogent Biosciences Shareholders Back Board, Governance Proposals
TipRanks · 3h ago
Assessing Cogent Biosciences (COGT) Valuation After A Strong One Year Run And Cooling Momentum
Simply Wall St · 2d ago
Weekly Report: what happened at COGT last week (0601-0605)?
Weekly Report · 3d ago
Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy
PUBT · 6d ago
Cogent Biosciences (COGT) Is Down 7.3% After Priority Review Win For Bezuclastinib Combo In GIST - Has The Bull Case Changed?
Simply Wall St · 6d ago
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations
Seeking Alpha · 06/02 14:10
Assessing Cogent Biosciences (COGT) Valuation After PEAK Phase 3 Success And FDA Priority Review
Simply Wall St · 06/02 07:22
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT)
TipRanks · 06/01 12:50
More
About COGT
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.